Emergency Use Protocol for EPI-743 in Acutely Ill Patients With Inherited Mitochondrial Respiratory Chain Disease Within 90 Days of End-of-Life Care

Trial Profile

Emergency Use Protocol for EPI-743 in Acutely Ill Patients With Inherited Mitochondrial Respiratory Chain Disease Within 90 Days of End-of-Life Care

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Mar 2016

At a glance

  • Drugs Vatiquinone (Primary)
  • Indications Mitochondrial disorders
  • Focus Therapeutic Use
  • Sponsors Edison Pharmaceuticals
  • Most Recent Events

    • 18 Mar 2016 Planned End Date changed from 1 Dec 2014 to 1 Dec 2017, as reported by ClinicalTrials.gov.
    • 18 Mar 2016 Planned primary completion date changed from 1 Dec 2014 to 1 Dec 2017, as reported by ClinicalTrials.gov.
    • 12 Feb 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top